BOXED WARNING Suicidality: increased risk of suicidal thinking/behavior in children, adolescents, and young adults. Not approved in pediatric patients.
FDA dosing
Population
Start
Target
Max
Major depressive disorder
Adults
75 mg/day divided BID–TID (with food)
Up to 225 mg/day
375 mg/day (severely depressed inpatients)
Titration Increase by up to 75 mg/day at intervals of no less than 4 days.
Renal Reduce total daily dose by 25% (mild–moderate, GFR 10–70); by 50% for hemodialysis.
Hepatic Reduce total daily dose by 50% (mild–moderate impairment); may need greater reduction in cirrhosis.
Instructions
Take with food
Administer in divided doses (2–3 times daily)
Taper gradually rather than abruptly stopping
Contraindications
MAOIs (for psychiatric disorders) concomitantly, within 7 days after stopping venlafaxine, or within 14 days of stopping an MAOI; do not start in patients treated with linezolid or IV methylene blue
Cautions
Serotonin syndrome
Increased blood pressure
Increased heart rate
Discontinuation symptoms
Activation of mania/hypomania
Adverse reactions
Nausea
Somnolence
Dry mouth
Dizziness
Sweating
Nervousness/anxiety
Constipation
Anorexia
Abnormal ejaculation/impotence
Tremor
Pregnancy No clear malformation risk; third-trimester exposure can cause neonatal complications (SSRI/SNRI class).
Lactation Undefined.
⚠ BOXED WARNING
Suicidal thoughts and behaviors in patients under 25